Gold prices bounce off 3-week lows; demand likely longer term
BLOOMFIELD - The Cigna Group (NYSE:CI), a prominent global health service company with a market capitalization of $85.13 billion and annual revenue of $247.12 billion, today announced significant changes to its leadership team, aimed at enhancing customer focus and accelerating growth. According to InvestingPro analysis, the company maintains a "GREAT" financial health score of 3.18, suggesting strong operational performance. Brian Evanko has been appointed as President and Chief Operating Officer, while Ann Dennison takes on the role of Executive Vice President and Chief Financial Officer.
Effective March 31, Evanko will oversee all business lines, reporting directly to David Cordani, Chairman and CEO of The Cigna Group. Evanko, who joined the company in 1998, has held various leadership roles, including President and CEO for Cigna Healthcare since January 2024, and Chief Financial Officer since 2021.
Dennison, who joined Cigna as Deputy CFO in early 2024, will now lead all enterprise financial operations. Her previous experience includes serving as CFO at Nasdaq and holding senior positions at Goldman Sachs.
Nicole Jones, currently Chief Administrative Officer and General Counsel, will expand her responsibilities to include Enterprise Marketing, aligning this function with other areas she manages.
Eric Palmer, President and CEO of Evernorth Health Services, will depart The Cigna Group at the end of April after a career spanning more than 25 years with the company.
The company also reaffirmed its full-year 2025 financial outlook, projecting a consolidated adjusted income from operations of at least $29.50 per share, with Evernorth pre-tax adjusted income from operations at a minimum of $7.2 billion, and Cigna Healthcare at $4.1 billion or more. InvestingPro data shows the company’s strong dividend performance, with 44 consecutive years of dividend maintenance and a recent dividend growth of 22.76%. The stock currently appears undervalued according to InvestingPro’s Fair Value analysis.
These announcements follow The Cigna Group’s previous discussion of its 2025 outlook during a January 30, 2025 press release and investor conference call, emphasizing the company’s commitment to growth and customer service. For deeper insights into Cigna’s valuation and growth prospects, investors can access the comprehensive Pro Research Report available on InvestingPro, which provides detailed analysis of the company’s financial health, market position, and future potential.
The information in this article is based on a press release statement from The Cigna Group.
In other recent news, Cigna Corporation has been in the spotlight due to several notable developments. Piper Sandler recently adjusted its outlook on Cigna by reducing the price target from $394 to $348, maintaining an Overweight rating. This change follows Cigna’s report of a significant earnings shortfall for the fourth quarter of 2024, primarily due to higher-than-expected costs in its Stop-Loss insurance. Cigna’s adjusted earnings per share of $6.64 fell short of the consensus estimate of $7.82. RBC Capital Markets also lowered its price target for Cigna from $377 to $355, citing challenges with high specialty drug costs and increased inpatient acuity affecting the company’s stop-loss insurance book.
Additionally, Cigna announced executive changes aimed at improving health outcomes and customer satisfaction, linking executive compensation to customer experience improvements. The company plans to publish an annual Customer Transparency Report starting in early 2026. In related industry news, healthcare stocks, including Cigna, experienced a recent uptick following President Trump’s supportive comments on social programs like Medicare and Medicaid. This development was perceived positively by investors, reflecting confidence in the stability of these programs. Meanwhile, the healthcare sector is under scrutiny due to a DOJ investigation into UnitedHealth Group’s Medicare billing practices, raising concerns about potential implications for other companies, including Cigna.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.